Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2007-11-19 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2007
Regulatory Filings
2007-11-19 Danish
Report Publication Announcement 2007
Report Publication Announcement Classification · 99% confidence The document is a short announcement (997 characters) from ALK-Abelló dated November 19, 2007, titled 'Telefonkonference' (Telephone Conference). It explicitly states that the company will hold a conference call today at 14:00 CET for analysts and investors to review and comment on the results of a Phase III study announced previously. This structure—announcing a call to discuss results—is characteristic of an Earnings Call or a related investor event discussion. Since the text is the announcement of the call itself, and not the transcript of the call, it fits best under Call Transcript (CT) if the call is about earnings/results, or potentially Regulatory Filing (RNS) if it's purely procedural. Given the context of discussing study results with analysts, it is highly related to investor communication surrounding results. However, the definition for 'Call Transcript' (CT) is 'Full text transcript of company conference calls (like earnings calls with Q&A)'. Since this document is the *invitation/notice* for the call, not the transcript, and it is not a formal regulatory filing like 10-K or ER, the most appropriate classification based on the provided definitions is to treat it as an announcement related to investor communication. Since there is no specific category for 'Call Announcement', and it is not the actual transcript (CT), nor the earnings release (ER), nor a general regulatory filing (RNS), I must re-evaluate. The content is purely about scheduling a discussion about results. If the discussion is an earnings call, the transcript would be CT. If this is merely an announcement of the call, it often falls under RNS as a general regulatory announcement, or sometimes IP if it's a presentation-style call. Given the short length and the focus on scheduling a discussion about results, RNS (Regulatory Filings - fallback) is a safe choice, but CT is often used broadly for earnings call related materials. Since the document is announcing the mechanism for discussing results, and not the results themselves (ER) or the transcript (CT), RNS is the most accurate fallback for an announcement of an event.
2007-11-19 English
Regulatory Filings 2007
Regulatory Filings
2007-11-16 Danish
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is an official announcement (Announcement No. 16 in 2007) directed to the Copenhagen Stock Exchange regarding the results of a clinical study (phase III results from US clinical study) for a product. It details scientific findings, safety profiles, and future development plans involving partners (Schering-Plough). This type of specific, material, non-financial operational update, especially one concerning clinical trials or regulatory progress, typically falls under general regulatory announcements or investor relations updates that are not covered by the specific financial report codes (10-K, IR, ER). Since it is a formal announcement to the exchange about a significant operational event (clinical trial results), and it doesn't fit the definitions for AGM-R, 10-K, ER, IR, or CT, the most appropriate general category for material, non-financial regulatory disclosures is Regulatory Filings (RNS). It is not a Director's Dealing (DIRS), a Dividend Notice (DIV), or a Capital Change (CAP).
2007-11-16 English
Regulatory Filings 2007
Regulatory Filings
2007-11-15 English
Regulatory Filings 2007
Regulatory Filings
2007-11-15 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.